人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白

Records for this ingredient, by country (identity only).

ATC L04AB · 1 markets · 8 records

人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 1 markets · 8 records Forms
Filters
MarketCN 8

CN 8 records · 2 shown of 2 Source 国家医保局 医保药品分类与代码数据库 · Data as of 2025-04-04

  • 25 mg per mL / per unit basis not statedinjection益赛普人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白Manufacturer: 三生国健药业(上海)股份有限公司、Manufacturer: 上海赛金生物医药有限公司、Manufacturer: 杭州博之锐生物制药有限公司
  • 12.5 mg per mL / per unit basis not statedinjection益赛普人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白Manufacturer: 杭州博之锐生物制药有限公司

Some strengths are recorded without a per mL / per unit basis. They are shown as recorded and are not compared with other markets.

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.

A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.